Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: A myocardial ischemia reduction with aggressive cholesterol lowering (MIRACL) substudy

Circulation

Volumn 106, Issue 13, 2002, Pages 1690-1695

  Waters, David D ^a,j   Schwartz, Gregory G ^b   Olsson, Anders G ^c   Zeiher, Andreas ^d   Oliver, Michael F ^e   Ganz, Peter ^f   Ezekowitz, Michael ^g   Chaitman, Bernard R ^h   Leslie, Sally J ⁱ   Stern, Theresa ⁱ  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c LINKÖPING UNIVERSITY   (Sweden)

^d GOETHE UNIVERSITY   (Germany)

^e NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^f HARVARD MEDICAL SCHOOL   (United States)

^g DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^h SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ PFIZER INC   (United States)

^j SAN FRANCISCO GENERAL HOSPITAL   (United States)

more..

Author keywords

Angina; Cholesterol; Myocardial infarction; Statins; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; HEPARIN; HYPOCHOLESTEROLEMIC AGENT; NITRATE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FATALITY; FEMALE; HEART ARREST; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HOSPITALIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SMOKING; STROKE; UNSTABLE ANGINA PECTORIS;

ACUTE DISEASE; AGED; ANGINA, UNSTABLE; ANTICHOLESTEREMIC AGENTS; CEREBROVASCULAR ACCIDENT; CHOLESTEROL; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HEPTANOIC ACIDS; HUMANS; INCIDENCE; LIPIDS; MALE; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; PROPORTIONAL HAZARDS MODELS; PYRROLES; RECURRENCE; RISK; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 0037167661     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000031568.40630.1C     Document Type: Article

References (28)

1. Mahaffey KW, Harrington RA, Simoons ML, et al. Stroke in patients with acute coronary syndromes: incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina receptor suppression using integrilin therapy (PURSUIT) trial. Circulation. 1999:99:2371-2377.
2. Pedersen TR, Kjekshus J, Pyörölä K. et al. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol. 1998:81:333-335.
3. Plehn JF, Davis BR, Sacks FM, et al, for the CARE Investigators. Reduction of stroke incidence after myocardial infarction with pravastatin: the CARE study. Circulation. 1999:216-223.
4. White HD, Simes J. Anderson NE, et al. Pravastatin therapy and the risk of stroke. N Engl J Med. 2000:343:317-326.
5. Iso H, Jacobs DR Jr. Wentworth D, et al. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. N Engl J Med. 1989:320:904-910.
6. Schwartz GG, Olsson AG. Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL Study: a randomized controlled trial. JAMA. 2001;285:1711-1718.
7. The GUSTO IIb Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med. 1996;335:673-682.
8. Cronin L, Mehta SR, Zhao F. et al for the OASIS investigators. Stroke in relation to cardiac procedures in patients with non-ST-elevation acute coronary syndrome: a study involving > 18,000 patients. Circulation. 2001;104:269-274.
9. Vaughn CJ, Delanty N. Neuroprotective properties of statins in cerebral ischemia and stroke. Stroke. 1999:30:1969-1973.
10. Crisby M, Nordin-Fredriksson G, Shah PK, et al. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation. 2001:103:926-933.
11. Furberg CD, Adams HP. Applegate WB. et al. for the Asymptomatic Carotid Plaque Study (ACAPS) Research Group. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation. 1994;90:1679-1687.
12. Undas A, Brummel KE, Musial J, et al. Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and Factor XIII and by enhancing factor Va inactivation. Circulation. 2001:103:2248-2253.
13. Lacoste L, Lam JYT. Hung J, et al. Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction. Circulation. 1995;:92:3172-3177.
14. Hashimoto H, Kitagawa K, Hougaku H, et al. C-reactive protein is an independent predictor of the rate of increase in early carotid atherosclerosis. Circulation. 2001;104:63-67.
15. Ridker PM, Cushman M, Stampfer MJ. et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973-979.
16. Jialal I, Stein D,. Balis D, et al. Effect of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation. 2001;103:1933-1935.
17. Endres M, Laufs U, Huang Z, et al. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci U S A. 1998;95:8880-8885.
18. Amin-Hanjani S, Stagliano NE, Yamada M. et al. Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice. Stroke. 2001;32:980-986.
19. Laufs U, Gertz K, Huang P, et al. Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice. Stroke. 2000;31:2437-2449.
20. Laufs U, Endres M, Custodis F, et al. Suppression of endothelial nitric oxide production after withdrawal of statin treatment is mediated by negative feedback regulation of Rho GTPase gene transcription. Circulation. 2000;102:3104-3110.
21. Samdani AF, Dawson TM, Dawson VL. Nitric oxide synthase in models of focal ischemia. Stroke. 1997;28:1283-1288.
22. Hu SX, Sheng WS, Peterson PK, et al. Differential regulation by cytokines of human astrocyte nitric oxide production. Glia. 1995;15:491-494.
23. Pahan K, Sheikh FG, Namboodiri AMS, et al. Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. J Clin Invest. 1997;100:2671-2679.
24. Okumura K, Iseki K, Wakugami K, et al. Low serum cholesterol as a risk factor for hemorrhagic stroke in men: a community-based mass screening in Okinawa, Japan. Jpn Circ J. 1999:63:53-58.
25. Leppala JM, Virtamo J, Fogelholm R, et al. Different risk factors for different stroke subtypes: association of blood pressure, cholesterol, and antioxidants. Stroke. 1999;30:2535-2540.
26. Bakker RG, Nawrocki JW, Black DM. Safety profile of atorvastatin-treated patients with low LDL-cholesterol levels. Atherosclerosis. 2000;149:123-129.
27. Barbesh GI, White HD, Modan M, et al, for the Investigators of the International Tissue Plasminogen Activator/Streptokinase Mortality Trial. Significance of smoking in patients receiving thrombolytic therapy for acute myocardial infarction: experience gleaned from the International Tissue Plasminogen Activator/Streptokinase Mortality Trial. Circulation. 1993:87:53-58.
28. Grines CL, Topol EJ, O'Neill WW, et al. Effect of cigarette smoking on outcome after thrombolytic therapy for myocardial infarction. Circulation. 1995;91:298-303.